![]() |
|
|
Vol. 26, Issue 3, 278-283, March 1998
National Institutes of Environmental Health Sciences (J.B., J.A.G.) and the Department of Anatomy, Physiological Sciences, and Radiology, College of Veterinary Medicine, North Carolina State University (S.A.B.)
| |
Abstract |
|---|
|
|
|---|
Two members of the canine cytochrome P4502C subfamily [CYP2C21 and CYP2C41 (sequence has been submitted to Genbank with accession number AF016248)] were cloned from three beagle liver cDNA libraries. The two canine CYP2C cDNAs exhibited 70% nucleotide and amino acid identity as well as 74-83% nucleotide and 67-76% amino acid identity with the human CYP2Cs. Canine CYP2C41 is more homologous to the human CYP2Cs than CYP2C21. The two canine CYP2C cDNAs exhibited a slightly lower nucleotide and amino acid identity (66-77%) with the rat P450CYPs, 2C11 and 2C12. Reverse transcription-polymerase chain reaction-based restriction enzyme tests for CYP2C21 and 2C41 mRNAs as well as polymerase chain reaction-based tests for genomic DNA were developed. CYP2C21 cDNA was present in the livers of all dogs tested (N = 9), but CYP2C41 was present in only 1 of the 9 (11%). Genomic tests found that the gene coding for CYP2C21 was also present in all dogs tested (N = 25), of which 15 were beagles and 10 mixed breeds. In contrast, the gene coding for CYP2C41 was present in only 16% (4 out of 25) of the dogs. An even distribution of the CYP2C41 gene was found between the sexes and between beagles and mixed breeds. This unique polymorphism in the canine CYP2C subfamily may be a source of variability in the metabolic clearance in dogs of xenobiotics that are metabolized by the cytochrome P450 2C subfamily of enzymes.
| |
Introduction |
|---|
|
|
|---|
The important role cytochrome P450
(P4501)
plays in the oxidative metabolism of xenobiotics as
well as many endogenous substances such as steroids and fatty acids has
long been recognized (Guengerich, 1990
). Multiple P450 isozymes have
been purified from various species. Of the most commonly used
laboratory animals, rat, mouse, and rabbit P450s have been the most
intensively studied. The development of molecular biology techniques
has led to the identification of rare P450s that would be difficult to
isolate using standard protein purification techniques and has allowed
greater insights into genetic heterogeneity and polymorphisms of P450
expression.
Despite the use of the dog in safety evaluation and efficacy studies of
new drugs, knowledge concerning the canine P450 system is limited. At
present, only a small number of canine liver P450 isozymes have been
identified and characterized. The most intensively studied of these has
been CYP2B11. This P450 has been isolated from dog liver microsomes
(Duignan et al., 1987
), identified by cloning techniques
(Graves et al., 1990
), and expressed in cDNA expression
systems (Kedzie et al., 1991
, 1993
; John et al.,
1994
). Other canine P450 cDNAs identified by cloning techniques include two members of the CYP1A subfamily (Fukuta et al., 1992
;
Uchida et al., 1990
), a member of the CYP2D subfamily
(CYP2D15) (Sakamoto et al., 1995
), and a member of the CYP3A
subfamily (Ciaccio et al., 1991
).
Komori et al. (1989)
purified a microsomal protein from male
beagle dog liver (P-450-D1) and proposed that it belonged to the CYP2
subfamily based on similarities in N-terminal amino acid sequence and
catalytic activities to rat CYP2C11. Subsequently, Uchida et
al. (1990)
isolated an 1875-base pair (bp) cDNA clone (DM1-1)
from a cDNA library from the liver of a male beagle dog belonging to
the CYP2 subfamily (CYP2C21). However, this clone was not full length.
Therefore, it was not possible to determine whether it was identical to
P-450-D1 isolated by Komori et al. (1989)
.
At present, four genes have been identified in the human CYP2C
subfamily (Goldstein and de Morais, 1994
) and five genes in the rat
CYP2C subfamily (Soucek and Gut, 1992
). Most of these genes are
constitutively expressed, and some members are polymorphic in each of
these species. In the rat, several members of the CYP2C subfamily are
gender specific in their expression. The specific aim of this study was
to determine whether additional members of the CYP2C subfamily exist in
the dog using molecular cloning techniques.
| |
Materials and Methods |
|---|
|
|
|---|
Tissue and Blood. Frozen liver tissue samples from untreated male and female beagle dogs were generously provided by M. Faletto and C. J. Serabjit-Singh at Glaxo-Wellcome (Research Triangle Park, NC) and by D. D. Christ at the DuPont-Merck Pharmaceutical Company (Wilmington, DE). Male and female canine whole blood samples from mixed and beagle breeds were obtained from the College of Veterinary Medicine, North Carolina State University (Raleigh, NC).
Materials.
Restriction endonucleases were purchased from New England Biolabs.
ZAP-cDNA synthesis and ZAP-cDNA Gigapack Gold cloning kits were
purchased from Stratagene, QIAamp blood and tissue kits and plasmid
kits from Qiagen, and cDNA synthesis kits from GIBCO-BRL. Transfer
membranes and [
-32P]dATP (6000 Ci/mmol) were
from DuPont Chemical Co., and kanamycin, ampicillin, and tetracycline
were obtained from Sigma.
RNA Isolation.
RNA was extracted from livers from nine beagle dogs (five females and
four males) by the method of Chomczynski and Sacchi (1987)
. Five µg
of RNA was reversed-transcribed into cDNA, using a cDNA synthesis kit
(GIBCO-BRL) and random hexamers or oligo(dT) (for library synthesis) as
primers.
cDNA Library Construction and Screening. Three Uni-ZAP XR cDNA libraries were constructed using the ZAP cDNA synthesis kit from Stratagene. Three libraries were constructed from hepatic RNA from two male beagle dogs and one female beagle. Poly(A+) RNA was prepared using oligo(dT)-cellulose columns (GIBCO-BRL) and reverse-transcribed using oligo(dT) as a primer. The cDNA was sized by fractionation on a Sephacryl S-500 spin column, ligated to Uni-ZAP XR arms, and packaged into Escherichia coli XL1-Blue MRF' cells using a Gigapack Gold III packaging kit as described by the manufacturer (Stratagene).
Approximately 5 × 104 recombinant phage plaques from each library were screened on nylon filters by plaque hybridization. The probe used to screen the cDNA libraries was a 275-bp hepatic canine cDNA PCR product based on the sequence data of canine CYP2C21 (DM1-1) cDNA (Uchida et al., 1990Genomic DNA from Liver and Blood. Purified genomic DNA from either liver or blood was extracted using the QIAamp tissue and blood kits, according to the manufacturer's recommendations. Hepatic DNA was obtained from 9 beagles, and blood DNA was obtained from another 19 dogs of both sexes, 9 beagles and 10 of mixed breeds.
Genetic Test to Discriminate between CYP2C21 and CYP2C41 cDNAs.
The strategy is outlined in fig. 1,
A and B. Two specific primers were used to
amplify exons 4 through 8 of both CYP2C21 and 2C41. The exon
nomenclature is based on the human 2C genes (de Morais et
al., 1993
). The forward and reverse primers were
5'-CTGTGCTCCCTGCAATGTG-3' and 5'-CCATGAAGTAGTCACTCTTC-3',
respectively. The underlined C in the forward primer represents a
mismatch with the CYP2C41 sequence. The PCR reaction involved an
initial denaturing step of 94°C for 1 min, followed by 38 cycles of
denaturing at 94°C for 20 sec, annealing at 55°C for 10 sec, and
extension at 72°C for 30 sec with a final extension of 5 min at
72°C. The 767-bp PCR product of this amplification was digested
overnight at 37°C in separate reactions with NdeI, which
digests the CYP2C21 fragment into two smaller fragments of 359 and 408 bp but does not digest CYP2C41, and BbsI, which digests the
fragment from CYP2C41 into two smaller fragments of 654 and 113 bp but
does not digest CYP2C21. The reactions were electrophoresed on a 3%
agarose gel.
|
Genetic Tests to Discriminate between CYP2C21 and CYP2C41 Genomic DNAs. Figure 2, A and B, outline the strategy used for this genetic test. Two specific primers were used to amplify a 124-bp product from exon 7 of both the CYP2C21 and 2C41 gene. The forward and reverse primers were 5'-TGAAAGTCCAGGAAGAGATT-3' and 5'-ACAAGGTCAATGTATCTCTG-3', respectively. Only the underlined nucleotides do not match the CYP2C21 sequence. The PCR reaction involved an initial denaturing step of 94°C for 2 min, followed by 39 cycles of denaturing at 94°C for 20 sec, annealing at 53°C for 10 sec, and extension at 72°C for 10 sec with a final extension of 5 min. The 124-bp PCR fragment from the amplification of exon 7 is digested overnight at 37°C in separate reactions with NlaIV, which digests the fragment from CYP2C21 gene into two smaller fragments of 45 and 79 bp but does not digest CYP2C41, and AciI, which digests the fragment from CYP2C41 into fragments of 87 and 37 bp but does not digest that from CYP2C21. The reactions were electrophoresed on a 4% agarose gel.
|
| |
Results and Discussion |
|---|
|
|
|---|
Canine cDNA Libraries.
Using the 275-bp canine CYP2C21 cDNA PCR product as a probe, 24 clones
were isolated from three cDNA libraries. These could be divided into
two members of the CYP2C subfamily. The first was similar to CYP2C21
(DM1-1) reported by Uchida et al. (1990)
. This CYP2C was
present in all three cDNA libraries. The longest insert (clone 5b) was
1.9 kilobase pairs long and encoded a polypeptide of 487 amino acid
residues.
|
|
Genetic Tests. CYP2C41 was found only in the cDNA library from the one female beagle liver, not in the libraries from the two male beagle livers, suggesting that CYP2C41 could be either sex-specific or polymorphic in its expression. An RT-PCR-based restriction enzyme test was developed to discriminate between CYP2C21 and CYP2C41 mRNAs, and a second PCR test was developed to discriminate between the two canine CYP2Cs at the genomic level. Exons 4 to 8 of the two CYP2C cDNAs are amplified using common primers. The PCR products are digested first with NdeI, which digests CYP2C21 to fragments of 359 and 408 but does not digest CYP2C41. The PCR products are also digested separately with BbsI, which digests CYP2C41 but not CYP2C21 (fig. 1, A and B). Figure 1C shows the results of this cDNA genetic test from the livers of the three beagles used to construct the cDNA libraries. CYP2C41 was found only in dog no. 11, the female dog liver used to construct the cDNA library, although all three dogs contained CYP2C21. cDNA prepared from livers of six additional beagles (four females and two males) were tested and found to contain CYP2C21 but not CYP2C41 (data not shown), suggesting that the difference in the expression of CYP2C41 was not sex-dependent but represents a polymorphism.
To determine whether both genes are present in all dogs or whether CYP2C41 is present in certain dogs, a PCR-restrictive enzyme test was designed to discriminate the presence or absence of the two genes in the genomic DNA (fig. 2, A and B). Figure 2C shows the results from this genomic test from blood DNA of 19 dogs of both sexes. Ten of these dogs were of mixed breeds (A-J) and 9 were beagles (K-S). Also shown in fig. 2C are the results of this genomic test using liver DNA of six additional beagles of both sexes. It should be noted that dog no. 11, which represents the female beagle from which the CYP2C41 cDNA was isolated, was also positive for CYP2C41 in this genomic test, supporting the validity of the test. In addition to this female beagle, three other dogs exhibited the presence of the CYP2C41 gene, dogs G, I, and K. Dogs G and I were male dogs of mixed breeds, whereas dog K was a female beagle. As seen in the results of the cDNA genetic test, CYP2C21 was present in all 25 dogs (fig. 2C). The allele-specific PCR test for CYP2C21 and 2C41 gave similar results. Only in the DNA from the four dogs positive for CYP2C41, exon 7 also gave a 147-bp product for exon 4 of CYP2C41, whereas all the dogs were positive for CYP2C21 (data not shown). Thus, a 100% correlation was found between the two genomic tests. A summary of the incidence of CYP2C21 and CYP2C41 in the populations of dogs that were screened is shown in table 2. In 28 dogs, 14% (4/28) contained the CYP2C41 gene. Although this is a small population, it seems that the presence of CYP2C41 is independent of the breed (two beagles, two mixed breeds) of dog or gender (two males, two females). CYP2C21, on the other hand, was present in all 28 dogs.
|
| |
Acknowledgments |
|---|
We are grateful to M. Faletto and C. J. Serabjit-Singh from Glaxo-Wellcome (Research Triangle Park, NC) and D. D. Christ from DuPont-Merck Pharmaceutical Company (Wilmington, DE) for supplying the beagle liver tissue samples used in these studies.
| |
Footnotes |
|---|
Received August 20, 1997; accepted November 21, 1997.
Send reprint requests to: Stephen A. Bai, Department of Anatomy, Physiological Sciences, and Radiology, College of Veterinary Medicine, North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606.
| |
Abbreviations |
|---|
Abbreviations used are: P450, cytochrome P450; bp, base pair(s); RT-PCR, reverse transcription-polymerase chain reaction.
| |
References |
|---|
|
|
|---|
-hydroxylation of steroid sulfates.
Proc Natl Acad Sci USA
85:
4214-4217This article has been cited by other articles:
![]() |
M. Mise, T. Hashizume, and S. Komuro Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes Drug Metab. Dispos., September 1, 2008; 36(9): 1903 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Aidasani, M. J. Zaya, P. B. Malpas, and C. W. Locuson In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible Inhibition Drug Metab. Dispos., August 1, 2008; 36(8): 1512 - 1518. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tenmizu, K. Noguchi, H. Kamimura, H. Ohtani, and Y. Sawada THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR Drug Metab. Dispos., May 1, 2006; 34(5): 800 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lu, S. B. Singh, B. A. Carr, Y. Fang, C. D. Xiang, T. H. Rushmore, A. D. Rodrigues, and M. Shou Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12 J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 518 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mise, S. Yadera, M. Matsuda, T. Hashizume, S. Matsumoto, Y. Terauchi, and T. Fujii POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS Drug Metab. Dispos., February 1, 2004; 32(2): 240 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shou, R. Norcross, G. Sandig, P. Lu, Y. Li, Y. Lin, Q. Mei, A. D. Rodrigues, and T. H. Rushmore SUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450 Drug Metab. Dispos., September 1, 2003; 31(9): 1161 - 1169. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tibbitts Issues Related to the Use of Canines in Toxicologic Pathology--Issues With Pharmacokinetics and Metabolism Toxicol Pathol, January 1, 2003; 31(1_suppl): 17 - 24. [Abstract] [PDF] |
||||
![]() |
S. M. Lankford, S. A. Bai, and J. A. Goldstein Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986. [Abstract] [Full Text] |
||||
![]() |
S. K. Paulson, L. Engel, B. Reitz, S. Bolten, E. G. Burton, T. J. Maziasz, B. Yan, and G. L. Schoenhard Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib Drug Metab. Dispos., October 1, 1999; 27(10): 1133 - 1142. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||